These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34297177)

  • 1. Longitudinal clinical, cognitive, and neuroanatomical changes over 5 years in GBA-positive Parkinson's disease patients.
    Leocadi M; Canu E; Donzuso G; Stojkovic T; Basaia S; Kresojević N; Stankovic I; Sarasso E; Piramide N; Tomic A; Markovic V; Petrovic I; Stefanova E; Kostic VS; Filippi M; Agosta F
    J Neurol; 2022 Mar; 269(3):1485-1500. PubMed ID: 34297177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tracking Cortical Changes Throughout Cognitive Decline in Parkinson's Disease.
    Filippi M; Canu E; Donzuso G; Stojkovic T; Basaia S; Stankovic I; Tomic A; Markovic V; Petrovic I; Stefanova E; Kostic VS; Agosta F
    Mov Disord; 2020 Nov; 35(11):1987-1998. PubMed ID: 32886420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson's Disease and Their First-Degree Unaffected Relatives.
    Thaler A; Kliper E; Maidan I; Herman T; Rosenberg-Katz K; Bregman N; Gurevich T; Shiner T; Hausdorff JM; Orr-Urtreger A; Giladi N; Mirelman A
    Brain Topogr; 2018 Nov; 31(6):1029-1036. PubMed ID: 29846835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study.
    Mak E; Su L; Williams GB; Firbank MJ; Lawson RA; Yarnall AJ; Duncan GW; Owen AM; Khoo TK; Brooks DJ; Rowe JB; Barker RA; Burn DJ; O'Brien JT
    Brain; 2015 Oct; 138(Pt 10):2974-86. PubMed ID: 26173861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Features of
    Malek N; Weil RS; Bresner C; Lawton MA; Grosset KA; Tan M; Bajaj N; Barker RA; Burn DJ; Foltynie T; Hardy J; Wood NW; Ben-Shlomo Y; Williams NW; Grosset DG; Morris HR;
    J Neurol Neurosurg Psychiatry; 2018 Jul; 89(7):702-709. PubMed ID: 29378790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cortical thinning across Parkinson's disease stages and clinical correlates.
    Wilson H; Niccolini F; Pellicano C; Politis M
    J Neurol Sci; 2019 Mar; 398():31-38. PubMed ID: 30682518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of Grey Matter Atrophy at Different Stages of Parkinson's and Alzheimer's Diseases and Relation to Cognition.
    Kunst J; Marecek R; Klobusiakova P; Balazova Z; Anderkova L; Nemcova-Elfmarkova N; Rektorova I
    Brain Topogr; 2019 Jan; 32(1):142-160. PubMed ID: 30206799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The clinical features of Parkinson's disease in patients with mutations and polymorphic variants of GBA gene].
    Senkevich KA; Miliukhina IV; Beletskaia MV; Gracheva EV; Kudrevatykh AV; Nikolaev MA; Emelyanov AK; Kopytova AE; Timofeeva AA; Yakimovskii AF; Pchelina SN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):81-86. PubMed ID: 29171494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of prodromal parkinsonian features in a cohort of
    Avenali M; Toffoli M; Mullin S; McNeil A; Hughes DA; Mehta A; Blandini F; Schapira AHV
    J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1091-1097. PubMed ID: 31221723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort.
    Beavan M; McNeill A; Proukakis C; Hughes DA; Mehta A; Schapira AH
    JAMA Neurol; 2015 Feb; 72(2):201-8. PubMed ID: 25506732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease.
    Davis MY; Johnson CO; Leverenz JB; Weintraub D; Trojanowski JQ; Chen-Plotkin A; Van Deerlin VM; Quinn JF; Chung KA; Peterson-Hiller AL; Rosenthal LS; Dawson TM; Albert MS; Goldman JG; Stebbins GT; Bernard B; Wszolek ZK; Ross OA; Dickson DW; Eidelberg D; Mattis PJ; Niethammer M; Yearout D; Hu SC; Cholerton BA; Smith M; Mata IF; Montine TJ; Edwards KL; Zabetian CP
    JAMA Neurol; 2016 Oct; 73(10):1217-1224. PubMed ID: 27571329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early cognitive decline after bilateral subthalamic deep brain stimulation in Parkinson's disease patients with GBA mutations.
    Mangone G; Bekadar S; Cormier-Dequaire F; Tahiri K; Welaratne A; Czernecki V; Pineau F; Karachi C; Castrioto A; Durif F; Tranchant C; Devos D; Thobois S; Meissner WG; Navarro MS; Cornu P; Lesage S; Brice A; Welter ML; Corvol JC;
    Parkinsonism Relat Disord; 2020 Jul; 76():56-62. PubMed ID: 32866938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical profiles of Parkinson's disease associated with common leucine-rich repeat kinase 2 and glucocerebrosidase genetic variants in Chinese individuals.
    Wang C; Cai Y; Gu Z; Ma J; Zheng Z; Tang BS; Xu Y; Zhou Y; Feng T; Wang T; Chen SD; Chan P;
    Neurobiol Aging; 2014 Mar; 35(3):725.e1-6. PubMed ID: 24095219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GBA-Associated Parkinson's Disease: Progression in a Deep Brain Stimulation Cohort.
    Lythe V; Athauda D; Foley J; Mencacci NE; Jahanshahi M; Cipolotti L; Hyam J; Zrinzo L; Hariz M; Hardy J; Limousin P; Foltynie T
    J Parkinsons Dis; 2017; 7(4):635-644. PubMed ID: 28777757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson's disease longitudinally.
    Hanganu A; Bedetti C; Degroot C; Mejia-Constain B; Lafontaine AL; Soland V; Chouinard S; Bruneau MA; Mellah S; Belleville S; Monchi O
    Brain; 2014 Apr; 137(Pt 4):1120-9. PubMed ID: 24613932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study.
    Szwedo AA; Dalen I; Pedersen KF; Camacho M; Bäckström D; Forsgren L; Tzoulis C; Winder-Rhodes S; Hudson G; Liu G; Scherzer CR; Lawson RA; Yarnall AJ; Williams-Gray CH; Macleod AD; Counsell CE; Tysnes OB; Alves G; Maple-Grødem J;
    Mov Disord; 2022 May; 37(5):1016-1027. PubMed ID: 35106798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression.
    Ortega RA; Wang C; Raymond D; Bryant N; Scherzer CR; Thaler A; Alcalay RN; West AB; Mirelman A; Kuras Y; Marder KS; Giladi N; Ozelius LJ; Bressman SB; Saunders-Pullman R
    JAMA Netw Open; 2021 Apr; 4(4):e215845. PubMed ID: 33881531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study.
    Alcalay RN; Caccappolo E; Mejia-Santana H; Tang M-; Rosado L; Orbe Reilly M; Ruiz D; Ross B; Verbitsky M; Kisselev S; Louis E; Comella C; Colcher A; Jennings D; Nance M; Bressman S; Scott WK; Tanner C; Mickel S; Andrews H; Waters C; Fahn S; Cote L; Frucht S; Ford B; Rezak M; Novak K; Friedman JH; Pfeiffer R; Marsh L; Hiner B; Siderowf A; Payami H; Molho E; Factor S; Ottman R; Clark LN; Marder K
    Neurology; 2012 May; 78(18):1434-40. PubMed ID: 22442429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-Glucocerebrosidase activity in
    Huh YE; Chiang MSR; Locascio JJ; Liao Z; Liu G; Choudhury K; Kuras YI; Tuncali I; Videnovic A; Hunt AL; Schwarzschild MA; Hung AY; Herrington TM; Hayes MT; Hyman BT; Wills AM; Gomperts SN; Growdon JH; Sardi SP; Scherzer CR
    Neurology; 2020 Aug; 95(6):e685-e696. PubMed ID: 32540937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival and dementia in GBA-associated Parkinson's disease: The mutation matters.
    Cilia R; Tunesi S; Marotta G; Cereda E; Siri C; Tesei S; Zecchinelli AL; Canesi M; Mariani CB; Meucci N; Sacilotto G; Zini M; Barichella M; Magnani C; Duga S; Asselta R; Soldà G; Seresini A; Seia M; Pezzoli G; Goldwurm S
    Ann Neurol; 2016 Nov; 80(5):662-673. PubMed ID: 27632223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.